Aclaris Therapeutics, Inc. Share Price & Technical Analysis
ACRS · $4.51 (-0.22%)
Healthcare / Biotechnology
$4.51
-0.22%
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic r…
Price chart
Seasonality
May has 3 positive and 2 negative years (last 5 years shown)
5% return in May, -5% avg return in past 3 year May month.
53% return in 2026, -1% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 17% | -17% | 36% | 13% | 5% | – | – | – | – | – | – | – | 53% |
| 25 | 0% | -17% | -25% | -7% | 7% | -7% | 7% | 27% | 0% | 32% | 4% | 7% | 28% |
| 24 | 9% | 0% | 0% | -8% | -17% | 10% | 18% | -14% | -8% | 50% | 128% | -39% | 129% |
| 23 | 6% | -26% | -35% | 10% | -6% | 24% | -4% | -24% | -9% | -26% | -82% | 11% | -161% |
| 22 | -26% | 35% | 15% | -28% | 3% | 9% | 11% | 3% | -1% | -2% | -4% | 2% | 18% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Uptrend · Uptrend
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an potent and selective novel investigational dual inhibitor of ITK and JAK3 in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in Phase 1b to treat various atopic, immunologic, and respiratory diseases; ATI-9494, an oral, covalent, investigational dual inhibitor of ITK and Resting Lymphocyte Kinase (TXK), and other covalent JAK-sparing ITK inhibitors to treat modulate T cell biology across various diseases; and Lepzacitinib, a soft JAK 1/3 inhibitor for the treatment of atopic dermatitis and other dermatologic conditions. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$678.07M
P/E ratio
—
52W high
$5.15
52W low
$1.27
Volume
7,07,640
Beta
0.78
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Aclaris Therapeutics, Inc. share price today?
- Aclaris Therapeutics, Inc. (ACRS) last traded around $4.51 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does ACRS have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for ACRS. Download the app for real-time alerts.
- How can I analyze Aclaris Therapeutics, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.